Bortenat 3.5 mg Injection

Bortezomib belongs to a class of medications known as proteasome inhibitors, which work by blocking the proteasome, a cellular structure responsible for breaking down and recycling proteins within cells. In cancer cells, particularly plasma cells affected by multiple myeloma, blocking this process leads to a buildup of proteins that the cell cannot manage, ultimately triggering the death of the cancer cell. It is commonly used as a key treatment for multiple myeloma, a cancer affecting plasma cells in the bone marrow, often as part of a combination treatment regimen alongside other medications like dexamethasone. Bortezomib is also used to treat certain types of mantle cell lymphoma, expanding its role in managing various blood cancers. The medication is administered through injection, either intravenously or subcutaneously, typically in a hospital or specialized oncology setting, allowing healthcare providers to closely monitor the patient during treatment. Treatment schedules and dosing are carefully individualized based on the specific condition, treatment phase, and the patient's overall health status. Regular monitoring, including blood counts and nerve function assessments, is an important part of care throughout treatment to help guide safe and effective dosing. Many patients experience meaningful disease control and improved outcomes as part of a comprehensive treatment plan involving Bortezomib. As with all targeted cancer therapies, Bortezomib injection should be administered under the close supervision of an experienced oncology healthcare team.